CN108697766A - C型钠尿肽变体在治疗骨关节炎中的用途 - Google Patents

C型钠尿肽变体在治疗骨关节炎中的用途 Download PDF

Info

Publication number
CN108697766A
CN108697766A CN201680081329.2A CN201680081329A CN108697766A CN 108697766 A CN108697766 A CN 108697766A CN 201680081329 A CN201680081329 A CN 201680081329A CN 108697766 A CN108697766 A CN 108697766A
Authority
CN
China
Prior art keywords
cnp
seq
gly
variants
cartilage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680081329.2A
Other languages
English (en)
Chinese (zh)
Inventor
C·A·奥尼尔
T·M·奥彭内尔
J·K·平克斯塔夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomarin Pharmaceutical Inc
Original Assignee
Biomarin Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharmaceutical Inc filed Critical Biomarin Pharmaceutical Inc
Publication of CN108697766A publication Critical patent/CN108697766A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201680081329.2A 2015-12-08 2016-12-08 C型钠尿肽变体在治疗骨关节炎中的用途 Pending CN108697766A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562264682P 2015-12-08 2015-12-08
US62/264,682 2015-12-08
PCT/US2016/065520 WO2017100400A2 (en) 2015-12-08 2016-12-08 Use of c-type natriuretic peptide variants to treat osteoarthritis

Publications (1)

Publication Number Publication Date
CN108697766A true CN108697766A (zh) 2018-10-23

Family

ID=59013378

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680081329.2A Pending CN108697766A (zh) 2015-12-08 2016-12-08 C型钠尿肽变体在治疗骨关节炎中的用途

Country Status (17)

Country Link
US (2) US11202819B2 (enExample)
EP (2) EP3386531B1 (enExample)
JP (1) JP7104625B2 (enExample)
KR (1) KR20180088459A (enExample)
CN (1) CN108697766A (enExample)
AU (2) AU2016365751B2 (enExample)
CA (1) CA3007315A1 (enExample)
DK (1) DK3386531T3 (enExample)
ES (1) ES2901769T3 (enExample)
HR (1) HRP20211908T1 (enExample)
HU (1) HUE057083T2 (enExample)
IL (1) IL259690B2 (enExample)
MX (1) MX2018006986A (enExample)
PL (1) PL3386531T3 (enExample)
PT (1) PT3386531T (enExample)
RU (1) RU2759679C2 (enExample)
WO (1) WO2017100400A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112752556A (zh) * 2018-04-27 2021-05-04 雷米生物科学公司 新的医疗装置、递送运载体及其制造
CN113423384A (zh) * 2019-02-11 2021-09-21 阿森迪斯药物生长障碍股份有限公司 Cnp缀合物的干燥药物制剂
CN116635027A (zh) * 2020-11-25 2023-08-22 普罗林科斯有限责任公司 C-利钠肽的延长释放水凝胶偶联物
WO2025179727A1 (zh) * 2024-02-29 2025-09-04 天津凯莱英生物科技有限公司 沃索利肽可溶性中间体、中间体制备方法及沃索利肽的制备方法

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017118693A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with large carrier moieties
CA3008017C (en) 2016-01-08 2024-01-02 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with reduced side-effects
BR112018011008A2 (en) 2016-01-08 2018-12-04 Ascendis Pharma Growth Disorders A/S low npr-c binding controlled release cnp agonists
EP3400022A1 (en) 2016-01-08 2018-11-14 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low initial npr-b activity
LT3400019T (lt) 2016-01-08 2022-12-12 Ascendis Pharma Growth Disorders A/S Cnp provaistai su prie žiedo fragmento prijungtu nešikliu
MX2018008050A (es) 2016-01-08 2018-08-23 Ascendis Pharma Growth Disorders As Agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada con estabilidad endopeptidasa neutral (nep) incrementada.
HUE062117T2 (hu) 2016-09-29 2023-09-28 Ascendis Pharma Growth Disorders As Kombinációs terápia szabályozott felszabadulású CNP agonistákkal
EP4337957A1 (en) * 2021-05-11 2024-03-20 Texas Tech University System Targeted selenium conjugates as countermeasures for pathogenic viruses and cells
MX2024007052A (es) * 2021-12-07 2024-09-05 Biomarin Pharm Inc Terapia de dnc.
AR130935A1 (es) 2022-11-02 2025-02-05 Novo Nordisk As Compuestos de cnp
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
WO2024194300A1 (en) 2023-03-20 2024-09-26 Ascendis Pharma Growth Disorders A/S Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia
KR20250098109A (ko) * 2023-12-21 2025-07-01 주식회사 펩트론 나트륨이뇨 펩타이드 유사체 및 이의 용도

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1960757A (zh) * 2004-03-31 2007-05-09 中尾一和 身高增加用组合物
CN1960758A (zh) * 2004-03-31 2007-05-09 中外制药株式会社 关节炎的治疗剂或预防剂
US20100331256A1 (en) * 2007-11-21 2010-12-30 Biomarin Pharmaceutical Inc. Variants of C-Type Natriuretic Peptides
CN102481330A (zh) * 2009-05-20 2012-05-30 生物马林药物股份有限公司 C型利钠肽变体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
JP2809533B2 (ja) 1991-01-31 1998-10-08 壽之 松尾 Ｃｎｐ類似体ペプチド
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
IL142118A0 (en) 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
CA2823066A1 (en) * 2010-12-27 2012-07-05 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1960757A (zh) * 2004-03-31 2007-05-09 中尾一和 身高增加用组合物
CN1960758A (zh) * 2004-03-31 2007-05-09 中外制药株式会社 关节炎的治疗剂或预防剂
US20100331256A1 (en) * 2007-11-21 2010-12-30 Biomarin Pharmaceutical Inc. Variants of C-Type Natriuretic Peptides
CN102481330A (zh) * 2009-05-20 2012-05-30 生物马林药物股份有限公司 C型利钠肽变体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DANIEL J WENDT ET AL.: "Neutral endopeptidase-resistant C-type natriuretic peptide variant represents a new therapeutic approach for treatment of fibroblast growth factor receptor 3-related dwarfism", 《J PHARMACOL EXP THER》 *
N J PEAKE ET AL.: "C-type natriuretic peptide signalling drives homeostatic effects in human chondrocytes", 《BIOCHEM BIOPHYS RES COMMUN》 *
NICK J PEAKE ET AL.: "Controlled release of C-type natriuretic peptide by microencapsulation dampens proinflammatory effects induced by IL-1β in cartilage explants", 《BIOMACROMOLECULES》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112752556A (zh) * 2018-04-27 2021-05-04 雷米生物科学公司 新的医疗装置、递送运载体及其制造
CN113423384A (zh) * 2019-02-11 2021-09-21 阿森迪斯药物生长障碍股份有限公司 Cnp缀合物的干燥药物制剂
CN113423384B (zh) * 2019-02-11 2024-01-05 阿森迪斯药物生长障碍股份有限公司 Cnp缀合物的干燥药物制剂
CN116635027A (zh) * 2020-11-25 2023-08-22 普罗林科斯有限责任公司 C-利钠肽的延长释放水凝胶偶联物
WO2025179727A1 (zh) * 2024-02-29 2025-09-04 天津凯莱英生物科技有限公司 沃索利肽可溶性中间体、中间体制备方法及沃索利肽的制备方法

Also Published As

Publication number Publication date
JP2019505486A (ja) 2019-02-28
AU2016365751B2 (en) 2023-12-21
PL3386531T3 (pl) 2022-02-28
HRP20211908T1 (hr) 2022-03-04
WO2017100400A2 (en) 2017-06-15
DK3386531T3 (da) 2022-01-03
EP4019038A2 (en) 2022-06-29
RU2018124600A3 (enExample) 2020-01-13
AU2024201852A1 (en) 2024-04-11
KR20180088459A (ko) 2018-08-03
EP3386531B1 (en) 2021-10-13
AU2016365751A1 (en) 2018-06-21
CA3007315A1 (en) 2017-06-15
IL259690A (en) 2018-07-31
IL259690B2 (en) 2023-02-01
HUE057083T2 (hu) 2022-04-28
ES2901769T3 (es) 2022-03-23
WO2017100400A3 (en) 2017-10-26
RU2018124600A (ru) 2020-01-13
IL259690B (en) 2022-10-01
US11202819B2 (en) 2021-12-21
US20190247467A1 (en) 2019-08-15
EP3386531A2 (en) 2018-10-17
RU2021132347A (ru) 2022-03-24
RU2759679C2 (ru) 2021-11-16
PT3386531T (pt) 2021-12-29
EP4019038A3 (en) 2022-09-28
JP7104625B2 (ja) 2022-07-21
US20220160836A1 (en) 2022-05-26
MX2018006986A (es) 2018-09-05
US12214015B2 (en) 2025-02-04

Similar Documents

Publication Publication Date Title
US12214015B2 (en) Use of c-type natriuretic peptide variants to treat osteoarthritis
JP6995933B2 (ja) インターロイキン２３受容体の経口ペプチド阻害剤および炎症性腸疾患を処置するためのそれらの使用
TWI471137B (zh) Ｃ型利鈉胜肽變異體
JP6858174B2 (ja) インターロイキン２３受容体のペプチド阻害剤、および炎症性疾患を処置するためのそれらの使用
US10328126B2 (en) Peptides and compositions for treatment of joint damage
TW200927758A (en) Variants of C-type natriuretic peptide
JP2017523959A (ja) ヘプシジンおよびミニ−ヘプシジンアナログおよびその使用
US20190270786A1 (en) Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases
JP2000516579A (ja) 腸栄養性ｇｌｐ―２ペプチドのアンタゴニスト
US20220331398A1 (en) Methods and compositions for treatment of cartilage damage and arthritis
RU2850341C2 (ru) Применение вариантов натрийуретического пептида типа c для лечения остеоартрита
HK40074902A (en) Use of c-type natriuretic peptide variants to treat osteoarthritis
HK1262398B (en) Use of c-type natriuretic peptide variants to treat osteoarthritis
RU2777504C2 (ru) Способы и композиции для лечения повреждения хряща и артрита
WO2023150693A2 (en) Neuregulin-4 analogs and methods of using thereof in disease treatment
HK40038214A (en) Peptides and compositions for treatment of joint damage

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination